Department of Radiation Oncology, H. Lee Moffitt Cancer Center, Tampa, Florida.
Department of Radiation Oncology, H. Lee Moffitt Cancer Center, Tampa, Florida.
Pract Radiat Oncol. 2013 Jan-Mar;3(1):32-39. doi: 10.1016/j.prro.2012.02.006. Epub 2012 Mar 30.
Fiducial markers have been integrated into the management of multiple malignancies to guide more precise delivery of radiation therapy (RT). Fiducials placed at the margins of esophageal tumors are potentially useful to facilitate both RT target delineation and image-guided RT (IGRT). In this study, we report on the stability of endoscopic ultrasound (EUS)-guided fiducial placement for esophageal cancers and utilization for radiation treatment planning and IGRT.
An institutional review board-approved database was queried for patients treated for esophageal cancer with chemoradiotherapy (CRT). Patients included in the analysis had a diagnosis of esophageal cancer, were referred for treatment with CRT, and had fiducials placed under EUS guidance. Images acquired at time of radiation treatment planning, daily IGRT imaging, post-treatment restaging, and surveillance scans were analyzed to determine the stability of implanted markers.
We identified 60 patients who underwent EUS-guided fiducial marker placement near the margins of their esophageal tumors in preparation for RT treatment planning. A total of 105 fiducial markers were placed. At time of CT simulation, 99 markers were visualized. Fifty-seven patients had post-treatment imaging available for review. Of the 100 implanted fiducials in these 57 patients, 94 (94%) were visible at time of RT simulation. Eighty-eight (88%) fiducials were still present post-treatment imaging at a median of 107 days (range, 33-471 days) after implantation.
EUS-guided fiducial marker placement for esophageal cancer aids in target delineation for radiation planning and daily IGRT. Fiducial stability is reproducible and facilitates conformal treatment with image-guided RT techniques.
基准标记物已被整合到多种恶性肿瘤的治疗中,以更精确地提供放射治疗(RT)。放置在食管肿瘤边缘的基准标记物对于帮助 RT 靶区勾画和图像引导放射治疗(IGRT)非常有用。在这项研究中,我们报告了内镜超声(EUS)引导的食管恶性肿瘤基准标记物放置的稳定性,以及它们在放射治疗计划和 IGRT 中的应用。
通过机构审查委员会批准的数据库,对接受放化疗(CRT)治疗的食管恶性肿瘤患者进行了查询。分析中包括的患者具有食管恶性肿瘤的诊断,被转诊接受 CRT 治疗,并且在 EUS 引导下放置了基准标记物。对在放射治疗计划、每日 IGRT 成像、治疗后分期和监测扫描时获得的图像进行分析,以确定植入标记物的稳定性。
我们确定了 60 例在接受 RT 治疗计划前在食管肿瘤边缘附近接受 EUS 引导的基准标记物放置的患者。共放置了 105 个基准标记物。在 CT 模拟时,有 99 个标记物可见。57 例患者的治疗后影像学资料可用于回顾。在这 57 例患者的 100 个植入基准标记物中,有 94 个(94%)在 RT 模拟时可见。在植入后中位数为 107 天(范围,33-471 天)的治疗后影像学检查中,仍有 88 个(88%)基准标记物存在。
EUS 引导的食管恶性肿瘤基准标记物放置有助于放射治疗计划的靶区勾画和每日 IGRT。基准标记物的稳定性可重复,并且有利于使用图像引导放射治疗技术进行适形治疗。